The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 301-306

  Chan, John K ^a   Tian, Chunqiao ^b   Fleming, Gini F ^c   Monk, Bradley J ^d   Herzog, Thomas J ^e   Kapp, Daniel S ^f   Bell, Jeffrey ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

Author keywords

Early stage epithelial ovarian cancer cycles chemotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CELL TYPE; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; EARLY CANCER; ENDOMETRIOID CARCINOMA; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RISK FACTORS; SURVIVAL RATE;

EID: 75949084199     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.073     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Averette H.E., Janicek M.F., and Menck H.R. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 76 (1995) 1096-1103
3. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23 (1996) 40-47
4. Hoskins P.J., Swenerton K.D., Manji M., et al. "Moderate-risk" ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation. Int. J. Gynecol. Cancer 4 (1994) 272-278
5. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. Int. J. Gynaecol. Obstet. 83 Suppl 1 (2003) 135-166
6. Kosary C.L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin. Surg. Oncol. 10 (1994) 31-46
7. Nguyen H.N., Averette H.E., Hoskins W., et al. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 72 (1993) 3007-3011
8. Dembo A.J., Davy M., Stenwig A.E., et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. 75 (1990) 263-273
9. Sevelda P., Vavra N., Schemper M., et al. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 65 (1990) 2349-2352
10. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322 (1990) 1021-1027
11. Finn C.B., Luesley D.M., Buxton E.J., et al. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br. J. Obstet. Gynaecol. 99 (1992) 54-58
12. Vergote I.B., Kaern J., Abeler V.M., et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am. J. Obstet. Gynecol. 169 (1993) 40-52
13. Bertelsen K., Holund B., Andersen J.E., et al. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int. J. Gynecol. Cancer 3 (1993) 211-218
14. Sjovall K., Nilsson B., and Einhorn N. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int. J. Gynecol. Cancer 4 (1994) 333-336
15. Ahmed F.Y., Wiltshaw E., A'Hern R.P., et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J. Clin. Oncol. 14 (1996) 2968-2975
16. Trope C., Kaern J., Hogberg T., et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann. Oncol. 11 (2000) 281-288
17. Chan J.K., Tian C., Monk B.J., et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 112 (2008) 2202-2210
18. Trimbos J.B., Vergote I., Bolis G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J. Natl. Cancer Inst. 95 (2003) 113-125
19. Colombo N., Guthrie D., Chiari S., et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 125-132
20. Young R.C., Brady M.F., Nieberg R.K., et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study. J. Clin. Oncol. 21 (2003) 4350-4355
21. Bell J., Brady M.F., Young R.C., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 102 (2006) 432-439
22. Bertelsen K., Jakobsen A., Stroyer J., et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol. Oncol. 49 (1993) 30-36
23. Hakes T.B., Chalas E., Hoskins W.J., et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol. Oncol. 45 (1992) 284-289
24. Lambert H.E., Rustin G.J., Gregory W.M., et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann. Oncol. 8 (1997) 327-333
25. Pectasides D., Fountzilas G., Aravantinos G., et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol. Oncol. 102 (2006) 285-291
26. Sugiyama T., Kamura T., Kigawa J., et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88 (2000) 2584-2589
27. Rothwell P.M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 (2005) 176-186
28. Mant D. Can randomised trials inform clinical decisions about individual patients?. Lancet 353 (1999) 743-746
29. Rothwell P.M. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 365 (2005) 82-93
30. Chan J.K., Teoh D., Hu J.M., et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109 (2008) 370-376
31. Fujita M., Enomoto T., Inoue M., et al. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn. J. Cancer Res. 85 (1994) 1247-1256
32. Willner J., Wurz K., Allison K.H., et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol. 38 (2007) 607-613
33. Enomoto T., Weghorst C.M., Inoue M., et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am. J. Pathol. 139 (1991) 777-785
34. Ichikawa Y., Nishida M., Suzuki H., et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 54 (1994) 33-35
35. Marquez R.T., Baggerly K.A., Patterson A.P., et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 11 (2005) 6116-6126
36. Zorn K.K., Bonome T., Gangi L., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11 (2005) 6422-6430
37. Vergote I., and Amant F. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. Gynecol. Oncol. 102 (2006) 415-417